Site provided by Valneva USA, Inc.

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

 

 

Never underestimate
the power of a bite.

Never underestimate
the power of a bite.

Japanese encephalitis is a potentially devastating neurologic disease1

A traveler to any of 24 countries in Asia can be infected with Japanese encephalitis (JE) virus,1 which is related to mosquito-borne Zika, dengue, yellow fever, and West Nile viruses.2 In rare cases, JE viral infection can result in encephalitis.1

Learn more about protecting travelers from Japanese encephalitis.

Reduce Risk for Your Patients by Knowing the Facts

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese encephalitis is not just in Japan


The Japanese encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.
1

JE occurs across Asia

Approximately 68,000 symptomatic cases of JE are estimated to occur each year in Asia.1

JE is the most common
vaccine-preventable encephalitis in Asia1,3


JE is the leading cause of viral-induced neurologic disability.1,3

Up to 30% who develop
JE die, and up to 50%
of JE survivors suffer
long-term sequelae
1,3 *

*Neurologic, cognitive, and psychiatric impairment1,4

There is no specific
treatment for JE3

Prevention is the best protection.3

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese encephalitis is not just in Japan


The Japanese encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.
1

JE occurs across Asia

Approximately 68,000 symptomatic cases of JE are estimated to occur each year in Asia.1

JE is the most common
vaccine-preventable encephalitis in Asia
1,3


JE is the leading cause of viral-induced neurologic disability.1,3

Up to 30% who develop JE die, and up to 50%
of JE survivors suffer long-term sequelae
1,4 *

*Neurologic, cognitive, and psychiatric impairment1,4

There is no specific
treatment for JE1,4

Prevention is the best protection.1,4

One vaccine can help
protect them

Learn about IXIARO®

JE is a devastating yet
vaccine-preventable disease.
1,3

Centers for Disease Control
and Prevention (CDC)

Learn more about risk reduction strategies
and vaccination for travelers at risk.

What is IXIARO?®

CDC Recommends

One vaccine can help protect them

Learn about IXIARO®

JE is a devastating yet
vaccine-preventable disease.
1,3

What is Ixiaro?®

Centers for Disease Control and Prevention (CDC)

Learn more about risk reduction strategies and vaccination for travelers at risk.

CDC Recommends

Indication & Usage

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO.  Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

Valneva USA, Inc.
910 Clopper Road, Suite 160S
Gaithersburg, MD 20878, USA

Customer Service
+1 866 223 7118

Medical Information
+1 844 349 4276
     (8443-IXIARO)

This website is intended for US-based healthcare professionals.

1807-US-IX-044-1018 | 10/18 | Copyright © 2018 Valneva USA, Inc. All Rights Reserved